作者:Melanie Marguerit、Gill Little、Yi Wang、Linli He、Shawn Allwein、James Reif、Jason Rossi、Renee Roemmele、Roger Bakale
DOI:10.1002/ejoc.201500906
日期:2015.12
A total synthesis of enantiomerically pure [14C]-labelled (–)-homoharringtonine in 17 steps is reported. This synthetic process enabled the production of Good Manufacturing Practice (GMP) compliant (–)-[14C]homoharringtonine that was used in a human mass balance study that was a post-approval commitment to the U.S. Food and Drug Administration. (–)-Homoharringtonine, also called omacetaxine mepesuccinate
据报道,对映体纯 [14C] 标记的 (–)-高三尖杉酯碱的全合成分为 17 个步骤。这种合成工艺能够生产符合良好生产规范 (GMP) 的 (–)-[14C] 高三尖杉酯碱,用于人体质量平衡研究,这是对美国食品和药物管理局的批准后承诺。(–)-Homoharringtonine,也称为 omacetaxine mepesuccinate,被批准用于治疗慢性粒细胞白血病 (CML)(一种血液和骨髓疾病)的成年患者。2012 年 11 月,该产品在美国商业化为 Synribo®,由 Teva Pharmaceuticals 销售。